Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: Int J Cancer. 2011 Oct 24;131(4):834–843. doi: 10.1002/ijc.26428

Figure 1. Targeting emmprin suppresses VEGF and IL-6 secretion during KSHV infection of endothelial cells.

Figure 1

(A, B) HUVEC were incubated with media (mock) or purified KSHV (K) for 2 h (A), in some cases following their transfection for 48 h with control siRNA (n-siRNA) or emmprin-siRNA (e-siRNA) (B). Cells were subsequently incubated in fresh media for an additional 24 h prior to performance of immunoblots to identify high (~65 kDa) and low (~35 kDa) MW glycoforms of emmprin. β-actin was identified for loading controls. Data shown represent one of three independent experiments. (C, D) Cells were treated as in (B) and concentrations of VEGF and IL-6 in culture supernatants determined using ELISAs. Error bars represent the S.E.M. for three independent experiments. ** = p<0.01.